Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeu...
Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics
About this item
Full title
Author / Creator
Publisher
Dordrecht: Springer Netherlands
Journal title
Language
English
Formats
Publication information
Publisher
Dordrecht: Springer Netherlands
Subjects
More information
Scope and Contents
Contents
Bacillus Calmette–Guerin (BCG) instillations are considered as a gold standard of therapy in high- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Unfortunately, up to 40% of patients might experience treatment failure and even 15% of patients initially diagnosed with NMIBC will progress to muscle-invasive disease. Since patients,...
Alternative Titles
Full title
Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2234482127
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2234482127
Other Identifiers
ISSN
0301-1623
E-ISSN
1573-2584
DOI
10.1007/s11255-019-02183-5
